ASH 2019 | New therapeutic standard for AML in remission: QUAZAR
Andrew Wei
• 10 Dec 2019
Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, discusses the primary results of QUAZAR AML-001 (NCT01757535), a phase 3 international, randomized, double-blind, placebo-controlled study evaluating an oral formulation of azacitidine (CC-486) as a maintenance therapy in older patients with acute myeloid leukemia (AML) in first remission following induction chemotherapy. Studies performed demonstrated that CC-486 has a manageable safety profile and represents a new therapeutic standard for patients with AML in remission. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
